📄 medicine

Serum Golgi Protein 73 as a Noninvasive Biomarker for Assessing Liver Diseases in a Tertiary Care Hospital

This prospective study conducted in a Nepalese tertiary care hospital demonstrates that serum Golgi Protein 73 (GP73) is a highly accurate noninvasive biomarker for distinguishing advanced chronic liver disease and severe fatty liver disease from early-stage fatty liver, outperforming conventional markers like FIB-4 and APRI.

Original authors: Narayan Gautam, Sujit Das, Parikshit Prasai, Sanju Rawal, Buddhi R. Pokhrel, Jharana Shrestha, Binaya Tamang, Binit K. Sharma, Samana Ghimire, Bilon Khambu, Prabodh Risal

Published 2026-07-15

📖 5 min read🧠 Deep dive

CC BY 4.0

Original authors: Narayan Gautam, Sujit Das, Parikshit Prasai, Sanju Rawal, Buddhi R. Pokhrel, Jharana Shrestha, Binaya Tamang, Binit K. Sharma, Samana Ghimire, Bilon Khambu, Prabodh Risal

Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). ✨ This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer

Imagine your liver is a busy, high-tech factory. Usually, it runs so smoothly that you don't even know it's there. But when the factory starts getting damaged—maybe from too much fatty sludge or chronic wear and tear—it starts leaking a very specific, secret signal into the bloodstream. For a long time, doctors have tried to listen for this signal using old, clunky radios (standard blood tests) that often pick up static from other parts of the body, like the heart or bones.

A new study from a hospital in Nepal suggests there's a much sharper, clearer radio frequency to tune into: a tiny protein called Golgi Protein 73, or GP73 for short.

The Secret Signal

Think of GP73 as a "distress flare" that the liver cells only shoot off when they are really stressed or injured. In this study, researchers looked at 85 people visiting a hospital, splitting them into three groups based on what their ultrasound scans showed:

The "Light Sludge" Group: People with mild fatty liver (Grade 1).
The "Heavy Sludge" Group: People with moderate fatty liver (Grade 2).
The "Factory in Trouble" Group: People with Chronic Liver Disease (CLD), where the damage is more serious.

The team measured the level of GP73 in everyone's blood. The result? The signal got louder and louder as the liver trouble got worse. It was like turning up the volume on a radio; the "Light Sludge" group had a quiet hum, while the "Factory in Trouble" group was screaming with a loud, clear signal.

The New Detective vs. The Old Tools

Doctors already have some tools to guess how bad the liver is, like the APRI score and the FIB-4 index. You can think of these as the "old flashlights" doctors used to use in the dark. They work okay, but sometimes they miss the details.

The researchers compared these old flashlights to the new GP73 "laser pointer." Here is what they found:

The Old Flashlights: The FIB-4 index was a decent flashlight (it got the job done about 82.7% of the time in spotting the trouble). The APRI score was a bit dimmer (about 75.7% accuracy).
The New Laser: The GP73 test was the sharpest tool in the box. It correctly identified the serious liver trouble 85.6% of the time.

The Magic Number

The study found a specific "tipping point" for this new test. If the GP73 level in the blood is 110 ng/mL or higher, it's a very strong sign that the liver has moved past mild fatty liver and is heading into more serious territory (like Grade 2 fatty liver or Chronic Liver Disease).

At this specific cutoff, the test was incredibly good at saying, "You are not in the serious danger zone" if the level was low. In fact, if the test said you were safe, it was right 97.05% of the time. That's like a security guard who almost never misses a real intruder but is also very good at letting the innocent people pass through.

What This Test Is NOT

It's important to know what this study didn't do.

It didn't prove it's the final answer: The researchers didn't perform liver biopsies (taking a tiny piece of liver tissue to look at under a microscope), which is the "gold standard" for seeing exactly what's happening inside. So, while the GP73 signal looks amazing, it hasn't been 100% matched against the tissue sample yet in this specific group.
It didn't predict the future: This was a snapshot in time. The study looked at patients right then, so it can't tell us if GP73 levels will predict who gets sick next year or five years from now.
It didn't work for everyone: The study explicitly ruled out people with certain solid tumors (like lung or colon cancer) or those on specific antiviral treatments, because those things can mess up the GP73 signal on their own.

The Bottom Line

The authors suggest that GP73 is a promising new "non-invasive" hero. "Non-invasive" means you don't need a needle stuck in your liver to get the answer; a simple blood draw is enough.

In places where fancy machines like FibroScans (which bounce sound waves off the liver) or biopsies are too expensive or unavailable, this new blood test could be a game-changer. It suggests that doctors might soon be able to tell the difference between a liver that's just a little greasy and one that's in serious trouble just by looking at this one number.

However, the authors are careful to say this is just the beginning. They need to test this on bigger groups of people and check it against actual tissue samples before we can say it's the new standard for everyone. For now, GP73 looks like a very bright new star in the sky of liver health, but we're still mapping the constellations.

Technical Summary: Serum Golgi Protein 73 as a Noninvasive Biomarker for Assessing Liver Diseases

Problem Statement
Chronic liver disease (CLD) and fatty liver disease (FLD) represent significant public health challenges, particularly in Nepal, with the potential to progress to fibrosis, cirrhosis, and hepatocellular carcinoma. While conventional liver function tests (LFTs) are standard for evaluation, they often lack the specificity required to accurately assess disease progression and severity. Furthermore, the gold standard for fibrosis staging, liver biopsy, is invasive and impractical for routine clinical use. There is a critical need for reliable, noninvasive biomarkers that can distinguish between early-stage liver pathology and advanced hepatic disease without the limitations of existing serological markers like AST, ALT, or calculated indices such as APRI and FIB-4.

Methodology
This prospective, single-center, cross-sectional study was conducted at the Universal College of Medical Sciences and Teaching Hospital in Bhairahawa, Nepal, between August 2025 and January 2026. The study enrolled 85 participants aged 30 years and older, categorized into two cohorts based on ultrasonographic findings:

Cohort 1 (Advanced Disease): Patients with Fatty Liver Disease Grade 2 (FLG2) and Chronic Liver Disease (CLD).
Cohort 2 (Early Disease): Patients with Fatty Liver Disease Grade 1 (FLG1).

Participants with solid tumors or those undergoing interferon therapy were excluded to prevent confounding effects on Golgi Protein 73 (GP73) levels. Serum GP73 levels were quantified using an automated chemiluminescence immunoassay (MAGLUMI 2000). Standard LFTs (AST, ALT, ALP, bilirubin, albumin, total protein) and platelet counts were measured using automated analyzers. The diagnostic performance of serum GP73 was compared against conventional LFTs and noninvasive fibrosis indices: the Aspartate Aminotransferase-to-Platelet Ratio Index (APRI) and the Fibrosis-4 (FIB-4) index. Statistical analysis included Receiver Operating Characteristic (ROC) curve analysis to determine diagnostic accuracy (AUC), optimal cutoff values, sensitivity, specificity, and predictive values. Correlation analyses were performed using Spearman's rank correlation coefficient.

Key Results

Demographics and Distribution: Among the 85 participants, 61.18% had FLG1, 27.06% had FLG2, and 11.76% had CLD. The study population was predominantly Hindu (92.94%) with a significant proportion of overweight or obese individuals.
GP73 Elevation: Serum GP73 levels demonstrated a statistically significant progressive increase with disease severity ( $p < 0.001$ ). The median GP73 level in the combined FLG2 and CLD group was markedly higher (59.10 ng/mL) compared to the FLG1 group (36.70 ng/mL).
Diagnostic Accuracy: GP73 showed the highest diagnostic performance for distinguishing advanced disease (FLG2/CLD) from early-stage fatty liver (FLG1).
- GP73: Achieved an Area Under the Curve (AUC) of 0.856 ( $p < 0.001$ ). At a cutoff value of 110 ng/mL, it demonstrated 80.00% sensitivity, 88.00% specificity, and a notably high Negative Predictive Value (NPV) of 97.05%.
- Comparison: GP73 outperformed the FIB-4 index (AUC = 0.827) and the APRI score (AUC = 0.757).
Correlations: Serum GP73 levels showed significant positive correlations with total bilirubin, direct/indirect bilirubin, AST, ALP, De Ritis ratio, APRI score, and FIB-4 index. Conversely, significant negative correlations were observed with serum albumin, total protein, and platelet count. No significant correlation was found with BMI.

Significance and Claims
The authors posit that serum GP73 is an emerging, effective noninvasive biomarker for identifying chronic liver disease and differentiating early-stage fatty liver disease from more advanced hepatic conditions like FLG2 and CLD. The study claims that GP73 offers superior diagnostic accuracy compared to established indices (APRI and FIB-4) within this specific tertiary care setting.

The authors highlight the clinical utility of GP73, particularly its high negative predictive value (97.05%), suggesting it could be valuable in settings where advanced imaging (e.g., transient elastography/FibroScan) or liver biopsies are unavailable or unaffordable. The paper concludes that while GP73 shows promise as an adjunctive tool, its routine application requires validation through larger, multicenter studies with histological confirmation. The authors explicitly acknowledge limitations, noting the lack of liver biopsy for direct histopathological correlation and the cross-sectional nature of the study, which precludes long-term prognostic evaluation.